

PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number	10/648,451
Filing Date	August 26, 2003
First Named Inventor	Aebi et al.
Art Unit	
Examiner Name	
Attorney Docket Number	20806 US1

Total Number of Pages in This Submission

5

ENCLOSURES (Check all that apply)

- | | | |
|---|--|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/
Incomplete Application
<input type="checkbox"/> Response to Missing Parts
under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a
Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication
to Group
<input type="checkbox"/> Appeal Communication to Board
of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input type="checkbox"/> Other Enclosure(s) (please
Identify below): |
|---|--|--|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	John R. Parise
Signature	
Date	November 26, 2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date November 26, 2003

Typed or printed	John R. Parise	Signature		Date	November 26, 2003
------------------	----------------	-----------	--	------	-------------------

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Aebe et al.

Group:

Serial No. 10/648,451, filed August 26, 2003

Examiner:

For: DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
November 26, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

None of the documents listed on Form PTO 1449 are being submitted because each document has been made of record in the parent application, Serial No. 10/014,959, filed December 11, 2001, now pending.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,



Attorney for Applicant(s)
John P. Parise
(Reg. No. 34,403)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-6326
Telefax: (973) 235-2363


136794

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/648,451
				Filing Date	August 26, 2003
				First Name Inventor	Aebi et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	20806 US1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Gotto et al., Circulation 81, pgs. 1721-1733 (1990)	
	C2	Stein et al., Nutr. Metab. Cardiovasc. Dis. 2, pgs. 113-156 (1992)	
	C3	Illingworth, Med. Clin. North Am. 84, pgs. 23-42 (2000)	
	C4	Ross et al., Arch. Intern. Med. 159, pgs. 1793-1802 (1999)	
	C5	Ellen et al., J. Cardiol. 81, pgs. 60B-65B (1998)	
	C6	Shepherd, Eur. Heart J. 16, pgs. 5-13 (1995)	
	C7	Davignon et al., Can. J. Cardiol 8, pgs. 843-864 (1992)	
	C8	Pedersen et al., Drug Safety 14, pgs. 11-24 (1996)	
	C9	Morand et al., J. Lipid Research 38, pgs. 373-390 (1997)	
	C10	Mark et al., J. Lipid Research 37, pgs. 148-158 (1996)	
	C11	Peffley et al., Biochem. Pharmacol 56, pgs. 439-449 (1998)	
	C12	Nelson et al., J. Biol. Chem. 256, pgs. 1067-1068 (1981)	
	C13	Spencer et al., J. Biol. Chem. 260, pgs. 13391-13394 (1985)	
	C14	Panini et al., J. Lipid Research 27, pgs. 1190-1204 (1986)	
	C15	Ness et al., Arch. Biochem. Biophys. 308, pgs. 420-425 (1994)	
	C16	Janowski et al., Proc. Natl. Acad. Sci. USA 96, pgs. 266-271 (1999)	
	C17	Venkateswaran et al., J. Biol. Chem. 275, pgs. 14700-14707 (2000)	
	C18	Costet et al., J. Biol. Chem. 275, pgs. 28240-28245 (2000)	
	C19	Ordovas et al., Nutr. Rev. 58, pgs. 76-79 (2000)	
	C20	Schmitz et al., Front. Biosci 6, D505-D514 (2001)	
	C21	Tobin et al., Mol. Endocrinol. 14, pgs. 741-752 (2000)	
	C22	Marshall et al., J. Org. Chem. 61(17), pgs. 5729-5735 (1996)	
	C23	Baker et al., J. Chem. Soc. Perkin Trans. 1, pgs. 1415-1421 (1990)	
	C24	Belostotskii et al., Tetrahedron Letters 35(28), pgs. 5075-5076 (1994)	
	C25	Bartlett et al., J. Am. Chem. soc. 106(25), pgs. 7854-7860 (1984)	
	C26	Cooper et al., Synthesis (4), pgs. 621-625 (2001)	
	C27	Stara et al., Collect. Czech. Chem. Commun. 64(4), pgs. 649-672 (1999)	
Examiner Signature			DATE CONSIDERED

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³Applicant is to place a check mark here if English language Translation or abstract is attached.